Leerink Partners Upgrades WAVE Life Sciences to Outperform, Announces $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar has upgraded WAVE Life Sciences (NASDAQ:WVE) from Market Perform to Outperform and set a price target of $12.
December 19, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners upgraded WAVE Life Sciences to Outperform and set a $12 price target, indicating a positive outlook for the stock.
Analyst upgrades typically lead to a positive short-term reaction in a stock's price as market sentiment improves. The new price target of $12 suggests a significant upside from the current trading level, which may attract investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100